newsfilter
← Latest News
Business Wire·

Alpine Immune Sciences Announces Pricing of $150 Million Public Offering

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the pricing of its underwritten